Company intelligence / Profile preview

Elysium Pharmaceuticals

Vadodara, Gujarat, Indiaelysiumpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Elysium Pharmaceuticals is an established Indian pharmaceutical contract manufacturer specializing in sterile formulations such as liquid and dry parenterals as well as nonsterile products like tablets, capsules, syrups, ointments. The company supplies both multinational pharma companies and leading Indian brands. It operates under ISO 9002 quality standards with GMP-compliant facilities near Vadodara. No proprietary clinical pipeline or novel drug development reported; focus is on manufacturing quality generics and branded products for partners.

Therapeutic areas: Other
Modalities: Small moleculeBiologic (sterile injectables, parenterals)Tabletscapsulessyrupsointments
Industry: Contract Manufacturing Organization

Partnerships

BayerZydus CadilaElder PharmaAventisTorrentNicholas Piramal

Beyond the preview

Go deeper on Elysium Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elysium Pharmaceuticals.

Explore the full profile